MetaCap

DBV Technologies S.A. (DBVT) vs Surrozen (SRZN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Surrozen (SRZN) has outperformed DBV Technologies S.A. (DBVT) over the past year, gaining 115.6% versus a loss of 34.4%. Over five years, DBVT leads with a +50.3% price change compared with -79.0% for SRZN. Surrozen is the larger company by market cap ($596.4 million vs $566.8 million), about 1.1 times the size, while DBV Technologies S.A. is growing revenue faster (+35.8% vs -67.4%).

DBV Technologies S.A. converts more of its revenue into profit, with a net margin of -2607.3% versus -6960.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DBVT-34.40%SRZN+115.61%
+168%+62%-45%
Nov 21, 20251 yearNov 20, 2026
DBVT+47.43%SRZN-79.38%
+321%+102%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DBVT versus SRZN key metrics
MetricDBVTSRZN
Share price$9.02$28.46
Market cap$566.82M$596.40M
1-day change-4.25%-7.21%
YTD return-52.95%+25.93%
1-year return-34.40%+115.61%
5-year return+50.33%-78.97%
EPS (TTM)$-3.00$-41.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.64M$3.48M
Revenue growth (YoY)+35.77%-67.37%
Net income (latest FY)$-146.95M$-242.03M
Operating margin-2609.23%-1210.58%
Net margin-2607.29%-6960.77%
52-week high$26.19$37.83
52-week low$8.63$12.79
Distance from 52-week high-65.55%-24.77%
Analyst consensusbuystrong_buy
Avg. price target upside+305.10%+123.12%
Average volume352.88K537.16K
Shares outstanding62.84M20.96M
Employees17944
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SRZN has outperformed DBVT by 150.0 percentage points over the past year.
  • DBV Technologies S.A. is more profitable, keeping -2607.3 cents of every revenue dollar as net income versus -6960.8 cents for Surrozen.
  • DBV Technologies S.A. grew revenue faster in its latest fiscal year (+35.77% vs -67.37%).

About DBV Technologies S.A.

DBVT stock →

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 179 employees

About Surrozen

SRZN stock →

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees

DBVT vs SRZN FAQ

Which is bigger, DBV Technologies S.A. or Surrozen?

Surrozen (SRZN) is larger, with a market capitalization of $596.40M compared with $566.82M for DBV Technologies S.A. (DBVT).

Which stock has performed better over the past year, DBVT or SRZN?

SRZN returned +115.61% over the past 12 months, compared with -34.40% for DBVT (price return, excluding dividends). Past performance does not predict future results.

Are DBV Technologies S.A. and Surrozen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons